Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MOREPENLAB.NS
Strong BuyPremium GrowerMorepen Laboratories Limited · Healthcare · India · $677M · Avg Vol: $38M/d
85
StockRankGet insider-trade alerts
Q
61
V
24
M
97
P/E (TTM)
45.3x
ROE
7.6%
D/E
0.2x
Dividend %
0.2%
COMPANY DESCRIPTION
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 14.1B | 16.8B | 18.0B | 18.0B | 8.4% | 19.5B |
| EPS (INR) | 0.77 | 1.88 | 2.20 | 1.73 | 31.0% | 2.57 |
| Shares | 511.2M | 511.2M | 548.0M | 548.0M | +7.2% | 548.0M |
| Debt | 251.6M | 290.0M | 1.1B | 2.1B | 102.1% | 2.1B |
| Equity | 7.5B | 8.5B | 11.6B | 12.5B | 18.3% | — |
| Op CF | -911.7M | 733.7M | 320.6M | 326.4M | -33.3% | 326.4M |
| Inv CF | -465.1M | -833.0M | -3.2B | -1.2B | — | — |
| Fin CF | 1.4B | 52.0M | 3.0B | 974.0M | — | — |
Loading 1Y...
PRICE (1Y)+106.6%
SMA 50SMA 200
Close
$1.23
RSI (14)
72.4
52W High
$1.29
From 52W High
1.0%
SCORE BREAKDOWN
Quality
61
ROIC
13.6%79.8
ROE
7.6%63.2
GP/Assets
37.4%74.6
Op. Margin
13.0%70.1
FCF/Assets
-6.6%33.1
Piotroski
549.3
Int. Cover
11.4x63.8
D/E Ratio
0.17x53.6
Current Ratio
2.37x46.1
Value
24
P/E (TTM)
45.3x24.3
EV/EBITDA
34.5x18.4
P/FCF
—N/A
P/B
5.3x27.1
P/S
3.3x54.1
Div Yield
0.2%3.9
Momentum
97
52W High %
95%93.7
RS 6M
195%99.2
SMA 50/200
1.53x98.3
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
425%96.3
FUNDAMENTALS
Market Cap
$677M
P/E (Forward)
—
Gross Margin
37.1%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MOREPENLAB.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MOREPENLAB.NS | Morepen Laboratories Limited(you) | $677M | 85 | Strong Buy |
| IOLCP.NS | IOL Chemicals and Pharmaceuticals Limited | $653M | 89 | Strong Buy |
| SPARC.NS | Sun Pharma Advanced Research Company Limited | $696M | 89 | Strong Buy |
| BLISSGVS.NS | Bliss GVS Pharma Limited | $810M | 87 | Strong Buy |
| INNOVACAP.NS | Innova Captab Limited | $707M | 79 | Buy |
| FDC.NS | FDC Limited | $594M | 76 | Buy |
| UNICHEMLAB.NS | Unichem Laboratories Limited | $413M | 87 | Strong Buy |
| RPGLIFE.NS | RPG Life Sciences Limited | $489M | 79 | Buy |
| AARTIDRUGS.NS | Aarti Drugs Limited | $406M | 80 | Strong Buy |
| VIYASH.NS | Viyash Scientific Limited | $1.2B | 88 | Strong Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%